Prothena(PRTA) - 2023 Q4 - Earnings Call Presentation

200 mg n= ~32 (3:1) - ascent-2 • Evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of PRX012 in patients with Alzheimer's disease 16 Anti-α-synuclein Antibody • 10 million patients globally5 Ongoing Phase 2b PADOVA (NCT04777331) • Primary Endpoint: Time to confirmed motor progression event 3-year change from baseline in MDS-UPDRS Part III OFF score7 NNC6019: Potential First-in-Class Treatment for ATTR Amyloidosis Tran Nguyen Chief Strategy Officer and Chief Financial ...